Sphera Funds Management’s TherapeuticsMD TXMD Stock Holding History

Sphera Funds Management’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-9,600	Closed	-$2.9M	–	144
2017 Q4	$2.9M	Buy	9,600 +2,000	+26%	+$557K	0.34%	74
2017 Q3	$2.01M	Sell	7,600 -4,000	-34%	-$1.16M	0.29%	85
2017 Q2	$3.06M	Hold	11,600	–	–	0.52%	58
2017 Q1	$4.18M	Buy	+11,600	New	+$3.59M	0.82%	31
2015 Q4	–	Sell	-10,250	Closed	-$3M	–	134
2015 Q3	$3M	Buy	10,250 +2,000	+24%	+$711K	0.38%	60
2015 Q2	$3.24M	Buy	8,250 +950	+13%	+$335K	0.32%	78
2015 Q1	$2.21M	Buy	+7,300	New	+$1.78M	0.23%	99

Other funds holding TXMD

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Sphera Funds Management's TXMD Position: Q1 2018 in Review

Sphera Funds Management sold out of TherapeuticsMD (TXMD) in Q1 2018, closing a stake of 9,600 shares — an estimated $2.9M sold.

Sphera Funds Management first reported a position in TXMD in Q1 2015 and held it in 7 quarters. The position peaked at $4.18M in Q1 2017. 143 funds tracked by Wall St. Rank hold TXMD as of Q1 2018.

Sphera Funds Management reported no remaining TherapeuticsMD position as of Q1 2018 after selling out during the quarter.
Sphera Funds Management sold 9,600 TherapeuticsMD shares in Q1 2018, an estimated $2.9M.
Sphera Funds Management first reported a position in TherapeuticsMD in Q1 2015 and held it in 7 quarters.
Sphera Funds Management's TherapeuticsMD position peaked at $4.18M in Q1 2017.
143 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2018.

Based on Sphera Funds Management's 13F filing for Q1 2018, filed 10 May 2018.